|
1
|
Meek DW and Marcar L: MAGE-A antigens as
targets in tumour therapy. Cancer Lett. 324:126–132. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
van der Bruggen P, Traversari C, Chomez P,
Lurquin C, De Plaen E, Van den Eynde B, Knuth A and Boon T: A gene
encoding an antigen recognized by cytolytic T lymphocytes on a
human melanoma. Science. 254:1643–1647. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chomez P, De Backer O, Bertrand M, De
Plaen E, Boon T and Lucas S: An overview of the MAGE gene family
with the identification of all human members of the family. Cancer
Res. 61:5544–5551. 2001.PubMed/NCBI
|
|
4
|
Kalejs M and Erenpreisa J: Cancer/testis
antigens and gametogenesis: A review and ‘brain-storming’ session.
Cancer Cell Int. 5:42005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
De Smet C, Lurquin C, Lethé B, Martelange
V and Boon T: DNA methylation is the primary silencing mechanism
for a set of germ line- and tumor-specific genes with a CpG-rich
promoter. Mol Cell Biol. 19:7327–7335. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sang M, Lian Y, Zhou X and Shan B: MAGE-A
family: Attractive targets for cancer immunotherapy. Vaccine.
29:8496–8500. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu W, Cheng S, Asa SL and Ezzat S: The
melanoma-associated antigen A3 mediates fibronectin-controlled
cancer progression and metastasis. Cancer Res. 68:8104–8112. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Marcar L, Ihrig B, Hourihan J, Bray SE,
Quinlan PR, Jordan LB, Thompson AM, Hupp TR and Meek DW: MAGE-A
cancer/testis antigens inhibit MDM2 ubiquitylation function and
promote increased levels of MDM4. PLoS One. 10:e01277132015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Marcar L, Maclaine NJ, Hupp TR and Meek
DW: Mage-A cancer/testis antigens inhibit p53 function by blocking
its interaction with chromatin. Cancer Res. 70:10362–10370. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang B, O'Herrin SM, Wu J, Reagan-Shaw S,
Ma Y, Bhat KM, Gravekamp C, Setaluri V, Peters N, Hoffmann FM, et
al: MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1
and suppress p53-dependent apoptosis in MAGE-positive cell lines.
Cancer Res. 67:9954–9962. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Monte M, Simonatto M, Peche LY, Bublik DR,
Gobessi S, Pierotti MA, Rodolfo M and Schneider C: MAGE-A tumor
antigens target p53 transactivation function through histone
deacetylase recruitment and confer resistance to chemotherapeutic
agents. Proc Natl Acad Sci USA. 103:11160–11165. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ladelfa M, Peche LY, Toledo MF, Laiseca
JE, Schneider C and Monte M: Tumor-specific MAGE proteins as
regulators of p53 function. Cancer Lett. 325:11–17. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Doyle JM, Gao J, Wang J, Yang M and Potts
PR: MAGE-RING protein complexes comprise a family of E3 ubiquitin
ligases. Mol Cell. 39:963–974. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gao Y, Mutter-Rottmayer E, Greenwalt AM,
Goldfarb D, Yan F, Yang Y, Martinez-Chacin RC, Pearce KH, Tateishi
S, Major MB and Vaziri C: A neomorphic cancer cell-specific role of
MAGE-A4 in trans-lesion synthesis. Nat Commun. 7:121052016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Brasseur F, Rimoldi D, Liénard D, Lethé B,
Carrel S, Arienti F, Suter L, Vanwijck R, Bourlond A, Humblet Y, et
al: Expression of MAGE genes in primary and metastatic cutaneous
melanoma. Int J Cancer. 63:375–380. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bergeron A, Picard V, LaRue H, Harel F,
Hovington H, Lacombe L and Fradet Y: High frequency of MAGE-A4 and
MAGE-A9 expression in high-risk bladder cancer. Int J Cancer.
125:1365–1371. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Črnjević Badovinac T, Spagnoli G, Juretić
A, Jakić-Razumović J, Podolski P and Šarić N: High expression of
MAGE-A10 cancer-testis antigen in triple-negative breast cancer.
Med Oncol. 29:1586–1591. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schultz-Thater E, Piscuoglio S, Iezzi G,
Le Magnen C, Zajac P, Carafa V, Terracciano L, Tornillo L and
Spagnoli GC: MAGE-A10 is a nuclear protein frequently expressed in
high percentages of tumor cells in lung, skin and urothelial
malignancies. Int J Cancer. 129:1137–1148. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kurg R, Reinsalu O, Jagur S, Õunap K, Võsa
L, Kasvandik S, Padari K, Gildemann K and Ustav M: Biochemical and
proteomic characterization of retrovirus Gag based microparticles
carrying melanoma antigens. Sci Rep. 6:294252016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rimoldi D, Salvi S, Schultz-Thater E,
Spagnoli G and Cerottini J: Anti-MAGE-3 antibody 57B and
anti-MAGE-1 antibody 6C1 can be used to study different proteins of
the MAGE-A family. Int J Cancer. 86:749–751. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Laban S, Atanackovic D, Luetkens T, Knecht
R, Busch CJ, Freytag M, Spagnoli G, Ritter G, Hoffmann TK, Knuth A,
et al: Simultaneous cytoplasmic and nuclear protein expression of
melanoma antigen-A family and NY-ESO-1 cancer-testis antigens
represents an independent marker for poor survival in head and neck
cancer. Int J Cancer. 135:1142–1152. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Piotti KC, Scognamiglio T, Chiu R and Chen
YT: Expression of cancer/testis (CT) antigens in squamous cell
carcinoma of the head and neck: Evaluation as markers of squamous
dysplasia. Pathol Res Pract. 209:721–726. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Russo AE, Torrisi E, Bevelacqua Y,
Perrotta R, Libra M, McCubrey JA, Spandidos DA, Stivala F and
Malaponte G: Melanoma: Molecular pathogenesis and emerging target
therapies (Review). Int J Oncol. 34:1481–1489. 2009.PubMed/NCBI
|
|
24
|
Rangwala S and Tsai KY: Roles of the
immune system in skin cancer. Br J Dermatol. 165:953–965. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ribero S, Moscarella E, Ferrara G, Piana
S, Argenziano G and Longo C: Regression in cutaneous melanoma: A
comprehensive review from diagnosis to prognosis. J Eur Acad
Dermatol Venereol. 30:2030–2037. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bååth R: Bayesian First Aid: A package
that implements Bayesian alternatives to the classical*. Test
functions in R. Proc Use R. 2014.
|
|
27
|
Robin X, Turck N, Hainard A, Tiberti N,
Lisacek F, Sanchez JC and Müller M: pROC: An open-source package
for R and S+ to analyze and compare ROC curves. BMC Bioinformatics.
12:772011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Saito T, Wada H, Yamasaki M, Miyata H,
Nishikawa H, Sato E, Kageyama S, Shiku H, Mori M and Doki Y: High
expression of MAGE-A4 and MHC class I antigens in tumor cells and
induction of MAGE-A4 immune responses are prognostic markers of
CHP-MAGE-A4 cancer vaccine. Vaccine. 32:5901–5907. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gjerstorff MF, Andersen MH and Ditzel HJ:
Oncogenic cancer/testis antigens: Prime candidates for
immunotherapy. Oncotarget. 6:15772–15787. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Barrow C, Browning J, MacGregor D, Davis
ID, Sturrock S, Jungbluth AA and Cebon J: Tumor antigen expression
in melanoma varies according to antigen and stage. Clin Cancer Res.
12:764–771. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Busam K, Iversen K, Berwick M, Spagnoli
GC, Old LL and Jungbluth AA: Immunoreactivity with the anti-MAGE
antibody 57B in malignant melanoma: Frequency of expression and
correlation with prognostic parameters. Mod Pathol. 13:459–465.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vinay DS, Ryan EP, Pawelec G, Talib WH,
Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HMCS, et
al: Immune evasion in cancer: Mechanistic basis and therapeutic
strategies. Semin Cancer Biol. 35 Suppl:S185–S198. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Brisam M, Rauthe S, Hartmann S, Linz C,
Brands RC, Kübler AC, Rosenwald A and Müller-Richter UD: Expression
of MAGE-A1-A12 subgroups in the invasive tumor front and tumor
center in oral squamous cell carcinoma. Oncol Rep. 35:1979–1986.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Groeper C, Gambazzi F, Zajac P, Bubendorf
L, Adamina M, Rosenthal R, Zerkowski HR, Heberer M and Spagnoli GC:
Cancer/testis antigen expression and specific cytotoxic T
lymphocyte responses in non small cell lung cancer. Int J Cancer.
120:337–343. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bricard G, Bouzourene H, Martinet O,
Rimoldi D, Halkic N, Gillet M, Chaubert P, Macdonald HR, Romero P,
Cerottini JC and Speiser DE: Naturally acquired MAGE-A10- and
SSX-2-specific CD8+ T cell responses in patients with
hepatocellular carcinoma. J Immunol. 174:1709–1716. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Valmori D, Dutoit V, Rubio-Godoy V,
Chambaz C, Liénard D, Guillaume P, Romero P, Cerottini JC and
Rimoldi D: Frequent cytolytic T-cell responses to peptide
MAGE-A10(254–262) in melanoma. Cancer Res. 61:509–512.
2001.PubMed/NCBI
|
|
37
|
Lee AK and Potts PR: A comprehensive guide
to the MAGE family of ubiquitin ligases. J Mol Biol. 429:1114–1142.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Arenberger P, Fialova A, Gkalpakiotis S,
Pavlikova A, Puzanov I and Arenbergerova M: Melanoma antigens are
biomarkers for ipilimumab response. J Eur Acad Dermatol Venereol.
31:252–259. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zajac P, Schultz-Thater E, Tornillo L,
Sadowski C, Trella E, Mengus C, Iezzi G and Spagnoli GC: MAGE-A
antigens and cancer immunotherapy. Front Med (Lausanne).
4:182017.PubMed/NCBI
|
|
40
|
Huang S, Okamoto T, Morton DL and Hoon DS:
Antibody responses to melanoma/melanocyte autoantigens in melanoma
patients. J Invest Dermatol. 111:662–667. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fishman P, Merimski O, Baharav E and
Shoenfeld Y: Autoantibodies to tyrosinase: The bridge between
melanoma and vitiligo. Cancer. 79:1461–1464. 1997. View Article : Google Scholar : PubMed/NCBI
|
